A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” mutant of Bcr-Abl

The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I ‘gatekeeper’ mutation. Here we describe a Type-II T315I inhibitor GNF-7, based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold whic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Choi, Hwan Geun, Ren, Pingda, Adrian, Francisco, Sun, Fangxian, Lee, Hyun Soo, Wang, Xia, Ding, Qiang, Zhang, Guobao, Zhang, Yongping, Liu, Yi, Tuntland, Tove, Warmuth, Markus, Manley, Paul W., Mestan, Jürgen, Gray, Nathanael S, Sim, Taebo
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134510/
https://ncbi.nlm.nih.gov/pubmed/20604564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm901808w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars